...
首页> 外文期刊>Clinical and Translational Allergy >Long-term inhaled corticosteroid treatment and severe asthma in children - the impact on body height and weight
【24h】

Long-term inhaled corticosteroid treatment and severe asthma in children - the impact on body height and weight

机译:长期吸入糖皮质激素治疗和小儿严重哮喘-对身高和体重的影响

获取原文

摘要

BackgroundChronic conditions such as asthma are usually stigmatizedas one of the reasons for short stature. A widespreadbelief also is that prolonged long-term treatmentwith corticosteroids will lead to elevated body weightand also could lead to short stature.Therefore we evaluated the height and weight statusin the children admitted in the hospital for asthmaattack regarding the asthma severity, the natural historyof asthma and inhaled corticosteroid (ICS) treatmentperiod.Material and methodFor a period of 6 months (Jan- Jun 2014) we evaluated100 (54 boys, mean age 7,48±0.53 and 46 girls, meanage 7.66±0.64) children admitted for asthma attack. Adetailed natural history, disease summary, pulmonaryfunction test, bronchodilation test and anthropometricdata were gathered, as well as data for a control groupof 132 patients with acute respiratory infectionsmatched by age and sex.Results49 asthmatic patients have been using ICS (18 for morethan 5 years). There were not any significant correlationsbetween height, weight, BMI (SDS) and the ICStreatment period, the time without controller therapy,BDR response, birth weight, the asthma duration, familyhistory or atopy status (p>0,05, r 0,01-0,2). No differenceswere found in height SDS when the kids werestratified according ICS treatment and its duration (lessor over 5 years)(p>0,1), the same results came for weight(p>0,1) and BMI (p>0,1). Comparing with the controlgroup, there is not a significant difference in weight(p=0,07 asthma vs controls, p=0,15 asthma on ICS vscontrols), height (p=0.06 asthma on ICS vs. controls).Severe asthma patients (11 on high dose combined corticosteroids± montelucast) also don’t show any significantdifference in height, BMI and weight compared toother asthma patients (p>0,5). Long-term not treatedasthmatics also don’t have any significant difference inanthropometric data compared to other asthmatics.ConclusionLong-term ICS therapy or not proper treatment is not thatdetermining for height and weight status in asthmapatients. Interesting future study would determinewhether there is a correlation between different food behaviorand exercise pattern that could lead the previouslypublished data.
机译:背景技术慢性病(例如哮喘)通常被人视为身材矮小的原因之一。人们普遍认为长期使用皮质类固醇激素会导致体重增加,也可能导致身材矮小。因此,我们评估了因哮喘发作而住院的儿童的身高和体重状况,包括哮喘的严重程度,哮喘的自然病史和材料和方法在为期6个月(2014年1月至2014年6月)中,我们评估了100名因哮喘发作而入院的儿童(54名男孩,平均年龄为7.48±0.53,46名女孩,平均年龄为7.66±0.64)。收集详细的自然病史,疾病摘要,肺功能测试,支气管扩张测试和人体测量学数据以及132例按年龄和性别匹配的急性呼吸道感染的对照组的数据。结果49例哮喘患者使用了ICS(18例超过5年)。 。身高,体重,BMI(SDS)与ICS治疗时间,无对照治疗的时间,BDR反应,出生体重,哮喘病持续时间,家族史或特应性状况之间无显着相关性(p> 0.05,r = 0.01) -0,2)。当根据ICS治疗对儿童进行分层时,身高SDS及其持续时间(小于5岁)(p> 0,1)没有差异,体重(p> 0,1)和BMI(p> 0, 1)。与对照组相比,体重(p = 0.07哮喘vs对照,p = 0.15哮喘(ICS vs对照)),身高(p = 0.06哮喘vs ICS与对照)无显着差异。与其他哮喘患者相比,在高剂量联合应用糖皮质激素治疗时,其身高,体重指数(BMI)和体重也无明显差异(p> 0.5)(11)。与其他哮喘患者相比,长期未接受治疗的哮喘患者的人体测量学数据也没有任何显着差异。结论长期ICS治疗或不适当的治疗并不能决定哮喘患者的身高和体重状况。有趣的未来研究将确定不同的饮食行为和运动方式之间是否存在相关性,从而可以指导先前发表的数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号